Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Calvert, Hilary; Twelves, Chris; Ranson, Malcolm; Plummer, Ruth; Fettner, Scott; Pantze, Michael; Ling, Jie; Hamilton, Marta; Lum, Bert L; Rakhit, Ashok.
; 25(7): 832-40, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24637575
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.
Effect of borneol on cytochrome P450 3A enzyme and midazolam pharmacokinetics in rats.
Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol.
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.